Cover Image
市場調查報告書

泌尿生殖系統相關的各種合作契約:契約條件·協定內容

Global Genitourinary Partnering 2010-2016: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 250303
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
泌尿生殖系統相關的各種合作契約:契約條件·協定內容 Global Genitourinary Partnering 2010-2016: Deal trends, players and financials
出版日期: 2016年09月01日 內容資訊: 英文
簡介

本報告提供的泌尿生殖系統相關的各種合作相關契約相關調查分析,近幾年的各種契約趨勢,大規模契約及大醫藥品經營者的契約概要,契約區分·開發現階段·技術區分·適應症各種類的名錄等彙整資料,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 泌尿生殖系統相關的各種契約趨勢

  • 簡介
  • 過去數年的泌尿生殖系統相關的合作
  • 大製藥公司的契約活動
  • 對泌尿生殖系統相關產業不積極的大型製藥公司
  • 泌尿生殖系統相關的合作:各類型契約
  • 泌尿生殖系統相關的合作:各產品部門
  • 泌尿生殖系統相關的合作:各開發階段
  • 泌尿生殖系統相關的合作:各技術類型
  • 泌尿生殖系統相關的合作:各適應症
  • 平均契約期間

第3章 主要契約

  • 簡介
  • 主要契約:各交易金額
  • 大型製藥公司相關的主要契約

第4章 大製藥公司的契約

  • 簡介
  • 大製藥公司的合作契約的利用法
  • 企業簡介

第5章 契約名錄

  • 簡介
  • 各類型契約
    • 資產購買
    • 轉讓
    • 主要的對外授權
    • 共同開發
    • 共同R&D
    • 服務契約
    • 共同促銷
    • 開發
    • 流通
    • 股票購買
    • 授權
    • 訴訟
    • 貸款
    • 製造
    • 行銷
    • 選擇
    • 推銷
    • 研究
    • 和解相關
    • 輔助許可證
    • 供給
    • 結束
  • 各開發階段
    • 藥物發明
    • 製劑設計
    • 上市
    • 階段I
    • 階段II
    • 階段III
    • 前臨床
    • 法規
  • 各技術類型
    • 化驗
    • 生物學的化合物
    • 血液製劑
    • 細胞治療
    • 設備
    • 藥物發明工具
    • 給藥
    • 設備
    • 器材
    • 基因治療
    • 基因學
    • 移植
    • 奈米技術
    • 胜肽
    • 蛋白質體學
    • 研究服務
    • 研究支援
    • RNA治療
    • 篩檢
    • 小分子

第6章 泌尿生殖系統相關的契約:各適應症

  • 簡介
  • 各適應症
    • 泌尿生殖系統
    • 急性腎損傷
    • 類澱粉沉積症
    • 慢性腎臟病
    • 膀胱炎
    • 糖尿病腎病變
    • 糖尿病
    • 頻尿
    • 失禁
    • 夜間頻尿
    • 急迫性尿失禁
    • 溶血性尿毒症
    • 腎臟結石
    • 膀胱過動症
    • 陰莖硬結症
    • 多發性囊胞腎
    • 前列腺疾病
    • 前列腺肥大
    • 前列腺炎
    • 腎功能衰竭
    • 腎炎
    • 泌尿道感染(UTI)

第6章 合作機會

  • 網路夥伴合作
  • 合作夥伴活動
  • 相關資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2208

The ‘Global Genitourinary Partnering 2010 to 2016: Deal trends, players and financials report’ provides comprehensive understanding and unprecedented access to the genitourinary partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Genitourinary Partnering 2010 to 2016’ provides the full collection of Genitourinary disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Genitourinary partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Genitourinary partnering agreement structure
  • Genitourinary partnering contract documents
  • Top Genitourinary deals by value
  • Most active Genitourinary dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genitourinary disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genitourinary deals.

The report presents financial deal terms values for Genitourinary deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genitourinary dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genitourinary dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genitourinary deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Genitourinary dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genitourinary deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genitourinary partnering deals by specific Genitourinary target announced since 2010. The chapter is organized by specific Genitourinary therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genitourinary partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genitourinary partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genitourinary technologies and products.

Report scope

‘Global Genitourinary Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Genitourinary trends and structure of deals entered into by leading companies worldwide.

‘Global Genitourinary Partnering 2010 to 2016’ includes:

  • Trends in Genitourinary dealmaking in the biopharma industry since 2010
  • Analysis of Genitourinary deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Genitourinary deal contract documents
  • Comprehensive access to over 3500 Genitourinary deal records
  • The leading Genitourinary deals by value since 2010
  • Most active Genitourinary dealmakers since 2010

The report includes deals for the following indications: Discharge, Frequency, Incontinence, Itching, Nocturia, Urgency, Acute kidney injury, Amyloidosis, Chronic kidney disease (CKD), Cystitis, Diabetic nephropathy, Dialysis, Hemolytic-uremic syndrome (HUS), Kidney stones, Nephrotic syndrom, Overactive bladder, Peyronie's disease, Polycystic kidney disease, Prostate diseases, Prostatitis, Prostate enlargement, Renal failure, Renal infections, Nephritis, Glomerulonephritis, Pyelonephritis, Vesicoureteral reflux, Urinary tract infection (UTI), plus other genitourinary indications.

In ‘Global Genitourinary Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Genitourinary Partnering 2010 to 2016’ report provides comprehensive access to available deals and contract documents for over 3500 Genitourinary deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise Genitourinary rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Genitourinary Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Genitourinary deal trends since 2010
  • Access Genitourinary deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Genitourinary partner companies
  • Comprehensive access to over 750 links to actual Genitourinary deals entered into by the world's biopharma companies
  • Indepth review of Genitourinary deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Genitourinary opportunities
  • Uncover companies actively partnering Genitourinary opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genitourinary dealmaking

  • 2.1. Introduction
  • 2.2. Genitourinary partnering over the years
  • 2.3. Genitourinary partnering by deal type
  • 2.4. Genitourinary partnering by industry sector
  • 2.5. Genitourinary partnering by stage of development
  • 2.6. Genitourinary partnering by technology type
  • 2.7. Genitourinary partnering by therapeutic indication

Chapter 3 -Financial deal terms for Genitourinary partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Genitourinary partnering
  • 3.3. Genitourinary partnering headline values
  • 3.4. Genitourinary deal upfront payments
  • 3.5. Genitourinary deal milestone payments
  • 3.6. Genitourinary royalty rates

Chapter 4 - Leading Genitourinary deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Genitourinary partnering
  • 4.3. List of most active dealmakers in Genitourinary
  • 4.4. Top Genitourinary deals by value

Chapter 5 - Genitourinary contract document directory

  • 5.1. Introduction
  • 5.2. Genitourinary partnering deals where contract document available

Chapter 6 - Genitourinary dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Genitourinary therapeutic target

Appendices

  • Appendix 1 - Directory of Genitourinary deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Genitourinary deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Genitourinary deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Genitourinary deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Genitourinary partnering since 2010
  • Figure 2: Genitourinary partnering by deal type since 2010
  • Figure 3: Genitourinary partnering by industry sector since 2010
  • Figure 4: Genitourinary partnering by stage of development since 2010
  • Figure 5: Genitourinary partnering by technology type since 2010
  • Figure 6: Genitourinary partnering by indication since 2010
  • Figure 7: Genitourinary deals with a headline value
  • Figure 8: Genitourinary deals with upfront payment values
  • Figure 9: Genitourinary deals with milestone payment
  • Figure 10: Genitourinary deals with royalty rates
  • Figure 11: Active Genitourinary dealmaking activity- 2010 to 2016
  • Figure 12: Top Genitourinary deals by value since 2010
Back to Top